Mary Adams

1.3k total citations
26 papers, 1.1k citations indexed

About

Mary Adams is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mary Adams has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Hematology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mary Adams's work include Multiple Myeloma Research and Treatments (10 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Treatment and Pharmacology (5 papers). Mary Adams is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Treatment and Pharmacology (5 papers). Mary Adams collaborates with scholars based in United States, United Kingdom and Switzerland. Mary Adams's co-authors include J. Blake Bartlett, Peter Schäfer, Lei Wu, David Stirling, George W. Muller, Troy Carter, Roger Chen, Peter J. Connolly, Angel R. Fuentes‐Pesquera and Stuart L. Emanuel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Mary Adams

24 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Adams United States 14 382 349 329 198 180 26 1.1k
Christian Beerli Switzerland 18 169 0.4× 170 0.5× 854 2.6× 231 1.2× 75 0.4× 31 1.2k
Tim P. Green United Kingdom 13 178 0.5× 504 1.4× 699 2.1× 81 0.4× 118 0.7× 14 1.2k
Da-Sheng Wang United States 12 68 0.2× 133 0.4× 696 2.1× 115 0.6× 112 0.6× 13 1.1k
David W. End United States 15 133 0.3× 301 0.9× 631 1.9× 46 0.2× 301 1.7× 26 1.1k
Sadao Kuromitsu Japan 19 118 0.3× 214 0.6× 500 1.5× 75 0.4× 192 1.1× 39 1.1k
Thomas Bohnacker Switzerland 16 177 0.5× 103 0.3× 624 1.9× 67 0.3× 33 0.2× 23 889
Christoph M. Dehnhardt United States 18 312 0.8× 135 0.4× 641 1.9× 103 0.5× 31 0.2× 22 938
Penglie Zhang United States 18 108 0.3× 583 1.7× 350 1.1× 41 0.2× 155 0.9× 37 1.2k
Christine Lambert‐van der Brempt United Kingdom 11 331 0.9× 243 0.7× 520 1.6× 50 0.3× 81 0.5× 20 925
Gengjie Yang United States 13 87 0.2× 289 0.8× 291 0.9× 50 0.3× 82 0.5× 21 814

Countries citing papers authored by Mary Adams

Since Specialization
Citations

This map shows the geographic impact of Mary Adams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Adams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Adams more than expected).

Fields of papers citing papers by Mary Adams

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Adams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Adams. The network helps show where Mary Adams may publish in the future.

Co-authorship network of co-authors of Mary Adams

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Adams. A scholar is included among the top collaborators of Mary Adams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Adams. Mary Adams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Henry, Jake Y., Ling Lu, Mary Adams, et al.. (2011). Lenalidomide enhances the anti‐prostate cancer activity of docetaxel in vitro and in vivo. The Prostate. 72(8). 856–867. 18 indexed citations
2.
Wu, Lei, Anastasia Parton, Ling Lu, et al.. (2010). Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunology Immunotherapy. 60(1). 61–73. 48 indexed citations
3.
Henry, Jake Y., et al.. (2010). Abstract 5386: Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Cancer Research. 70(8_Supplement). 5386–5386. 2 indexed citations
4.
Henry, Jake Y., et al.. (2010). Abstract A43: Lenalidomide enhances the anti-proliferative activity of docetaxel in in vivo and in vitro models of prostate cancer. Clinical Cancer Research. 16(14_Supplement). A43–A43.
5.
Lin, Ronghui, Sigmond G. Johnson, Peter J. Connolly, et al.. (2009). Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(8). 2333–2337. 112 indexed citations
6.
Zhang, Linghua, Mary Adams, Jolanta Kosek, Peter Schäfer, & J. Blake Bartlett. (2009). Lenalidomide Inhibits Multiple Myeloma Cell Proliferation in Vitro Via Its Effect On Expression of Oncogenes and Tumor Suppressor Genes.. Blood. 114(22). 2855–2855. 2 indexed citations
7.
Xu, Guozhang, Terry V. Hughes, Peter J. Connolly, et al.. (2008). Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 18(12). 3495–3499. 48 indexed citations
8.
Hughes, Terry V., Guozhang Xu, Steven K. Wetter, et al.. (2008). A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: Design, synthesis, and biological activity. Bioorganic & Medicinal Chemistry Letters. 18(17). 4896–4899. 24 indexed citations
9.
Xu, Guozhang, M.C. Abad, Peter J. Connolly, et al.. (2008). 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(16). 4615–4619. 80 indexed citations
10.
Huang, Shenlin, Ronghua Li, Peter J. Connolly, et al.. (2007). Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1). Bioorganic & Medicinal Chemistry Letters. 17(8). 2179–2183. 11 indexed citations
11.
Emanuel, Stuart L., Terry V. Hughes, Mary Adams, et al.. (2007). Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors. Molecular Pharmacology. 73(2). 338–348. 30 indexed citations
12.
Bartlett, J. Blake, Liangxing Wu, Mary Adams, et al.. (2007). Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab. Journal of Clinical Oncology. 25(18_suppl). 3023–3023. 12 indexed citations
13.
Lin, Ronghui, George Chiu, Yang Yu, et al.. (2007). Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(16). 4557–4561. 111 indexed citations
14.
Lin, Ronghui, Peter J. Connolly, Yanhua Lü, et al.. (2007). Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents. Bioorganic & Medicinal Chemistry Letters. 17(15). 4297–4302. 75 indexed citations
15.
Adams, Mary, Weisheng Lin, & Yinfa Ma. (2007). Quantitative Determination of ZnO Nano-Particles in Human Bronchoalveolar Carcinoma-Derived Lung Cancer Cells. 6(1).
16.
Peter, Christoph, Jan T. Kielstein, Mary Adams, et al.. (2007). A Novel Bioluminescent Tumor Model of Human Renal Cancer Cell Lines: An In Vitro and In Vivo Characterization. The Journal of Urology. 177(6). 2342–2346. 8 indexed citations
17.
Lin, Ronghui, Yanhua Lü, Steven K. Wetter, et al.. (2005). 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation. Bioorganic & Medicinal Chemistry Letters. 15(9). 2221–2224. 21 indexed citations
18.
Wacker, Michael, et al.. (2005). Detection of thromboxane A2 receptor mRNA in rabbit nodose ganglion neurons. Neuroscience Letters. 386(2). 121–126. 13 indexed citations
19.
Boyer, José L., Mary Adams, R. Gnana Ravi, Kenneth A. Jacobson, & T. Kendall Harden. (2002). 2‐Chloro N6‐methyl‐(N)‐methanocarba‐2′‐deoxyadenosine‐3′,5′‐bisphosphate is a selective high affinity P2Y1 receptor antagonist. British Journal of Pharmacology. 135(8). 2004–2010. 78 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian Beerli Breakdown of academic impact, for papers by Tim P. Green Breakdown of academic impact, for papers by Da-Sheng Wang Breakdown of academic impact, for papers by David W. End Breakdown of academic impact, for papers by Sadao Kuromitsu Breakdown of academic impact, for papers by Thomas Bohnacker Breakdown of academic impact, for papers by Christoph M. Dehnhardt Breakdown of academic impact, for papers by Penglie Zhang Breakdown of academic impact, for papers by Christine Lambert‐van der Brempt Breakdown of academic impact, for papers by Gengjie Yang
Rankless by CCL
2026